A group of 485 independently owned pharmacies nationwide has sued OptumRx, the successor company to Catamaran Corp. through a merger, claiming they were low-balled on reimbursements based on outdated pricing data.

The complaint claims that the company earns $60 billion dollars a year managing 1.2 billion prescriptions annually.

“Since Jan. 1, 2012, and continuing through the present date, Catamaran has set unreasonably low reimbursement rates, known as maximum allowable cost or 'MAC' pricing, based on irrelevant, inapplicable or outdated pricing data, or, in some cases, no data at all,” the complaint said. “Specifically, Catamaran consistently pays pharmacies MAC prices below the pharmacy's acquisition cost, in violation of its contract with the pharmacies.”